epcoritamab news

All news on epcoritamab (also known as epcoritamab-bysp and Epkinly): plants, production capacities, investments and involved companies.

11 June 2026

Genmab: Epcoritamab plus R2 shows consistent benefit across EPCORE FL‑1 subgroups

Post‑hoc subgroup analysis of the Phase 3 EPCORE FL‑1 shows epcoritamab+rituximab+lenalidomide delivers consistent PFS, ORR and CRR gains with a manageable safety profile across risk and fitness subgroups.

Who will be producing epcoritamab in the future?

Find out with chemXplore Alpha

Learn more